You are here: Home Published Research Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies.

Laura L Hammitt, Donald O Akech, Susan C Morpeth, Angela Karani, Norbert Kihuha, Sammy Nyongesa, Tahreni Bwanaali, Edward Mumbo, Tatu Kamau, Shahnaaz K Sharif, and J. AG Scott (2014)

Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies.

The Lancet. Global health, 2(7):e397–e405.

The effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countries was enhanced by indirect protection of unvaccinated individuals, mediated by reduced nasopharyngeal carriage of vaccine-serotype pneumococci. The potential indirect protection of 10-valent PCV (PCV10) in a developing country setting is unknown. We sought to estimate the effectiveness of introduction of PCV10 in Kenya against carriage of vaccine serotypes and its effect on other bacteria.

Adolescent, Adult, Age Distribution, Carrier State, Child, Child, Preschool, Cross-Sectional Studies, Developing Countries, Female, Haemophilus influenzae, Humans, Immunization Programs, Infant, Kenya, Male, Middle Aged, Nasopharynx, Pneumococcal Infections, Pneumococcal Vaccines, Population Surveillance, Streptococcus pneumoniae, Treatment Outcome, Young Adult
Adolescent, Adult, Age Distribution, Carrier State, Child, Child, Preschool, Cross-Sectional Studies, Developing Countries, Female, Haemophilus influenzae, Humans, Immunization Programs, Infant, Kenya, Male, Middle Aged, Nasopharynx, Pneumococcal Infections, Pneumococcal Vaccines, Population Surveillance, Streptococcus pneumoniae, Treatment Outcome, Young Adult
 
Document Actions